Key Highlights: Implications: Anyra smashes Eylea pricing barriers, flooding retina clinics with budget-friendly therapy that keeps patients compliant for years. Zydus seizes op...
Key Highlights: Implications: Tishtha detonates pricing bombs on Roche’s Tecentriq and MSD’s Opdivo, handing cash-strapped hospitals a lifeline while exploding p...
